Description
MVA-209 is currently under investigation for the treatment of colorectal cancer (CRC) and other solid tumors. Its efficacy and safety are being evaluated in clinical trials as a potential immunotherapy option, particularly in patients with advanced or refractory CRC.
Mechanism of Action
MVA-209 is an investigational oncolytic virus that selectively replicates in and kills cancer cells, while stimulating the immune system to target tumor cells.
Side Effects
Flu-like symptoms; rash; fatigue; nausea; vomiting
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT04041310
Phase 1
Active, not recruiting
Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
United States, Belgium, Canada, Italy, Spain, United Kingdom